/ Lyrica, developed by Pfizer, is a 3-substituted analog of γ-aminobutyric acid as a related compound to the company's gabapentin / neurontin, a commercially successful antiepileptic drug, The expected successor, July 2004, has been approved by the European Union as an adjunctive therapy for the management of peripheral neuropathic pain and for partial epileptic seizures.
Pregabalin was also approved in the United States at the end of December 2004 for the purpose of alleviating neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia, making it the first official U.S. approval to treat both Neuropathic pain treatment drugs, in 2005 and received FDA approval for partial seizures in patients with adult epilepsy adjuvant therapy.
June 2007 FDA approves Lyrica for the treatment of fibromyalgia, the first FDA-approved drug to treat fibromyalgia. Up to now, pregabalin is also the only anticonvulsant approved for the treatment of fibromyalgia. Because pregabalin has a very strong analgesic effect with few adverse effects, it has become a leader in anticonvulsants for the treatment of neuropathic pain.
It can be seen from the above that pregabalin has been approved as part of the epileptic seizures, diabetic peripheral neuropathy-related neuralgia, post-herpetic neuralgia, fibromyalgia, its wide range of applicability. The drug is listed as a blockbuster drug on the market.
In our small-scale epilepsy drug market, but huge population of diabetic patients, the drug is expected to get good sales only for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. In addition to other indications, the drug is expected to have a spectacular market size .
Although the treatment market for pregabalin indications in the country is not yet mature, such as the treatment of diabetic peripheral neuropathies and fibromyalgia, pregabalin is a potentially more potent product for producing If companies can be patient and do marketing work, the future will be a good return.